JP2008528517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528517A5 JP2008528517A5 JP2007552407A JP2007552407A JP2008528517A5 JP 2008528517 A5 JP2008528517 A5 JP 2008528517A5 JP 2007552407 A JP2007552407 A JP 2007552407A JP 2007552407 A JP2007552407 A JP 2007552407A JP 2008528517 A5 JP2008528517 A5 JP 2008528517A5
- Authority
- JP
- Japan
- Prior art keywords
- piperazin
- phenyl
- methylsulfonyl
- ethyl
- benzenamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- -1 alkyl amide Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 150000002148 esters Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- AOEODTYOLPPIBZ-UHFFFAOYSA-N n-[1-(6-chloro-1,3-benzodioxol-4-yl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline Chemical compound C=1C(Cl)=CC=2OCOC=2C=1C(C)NC(C(=CC=1)S(C)(=O)=O)=CC=1N1CCNCC1 AOEODTYOLPPIBZ-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003457 sulfones Chemical class 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 125000005907 alkyl ester group Chemical group 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- GKBZOLSBVYVOBV-UHFFFAOYSA-N 1-[2-[(3,5-dichlorophenyl)methylamino]-4-piperazin-1-ylphenyl]-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)C1=CC=C(N2CCNCC2)C=C1NCC1=CC(Cl)=CC(Cl)=C1 GKBZOLSBVYVOBV-UHFFFAOYSA-N 0.000 claims 1
- XYTWFDVIPOQUTP-UHFFFAOYSA-N 1-[2-[(3-bromophenyl)methylamino]-4-piperazin-1-ylphenyl]-2,2,2-trifluoroethanone Chemical compound FC(F)(F)C(=O)C1=CC=C(N2CCNCC2)C=C1NCC1=CC=CC(Br)=C1 XYTWFDVIPOQUTP-UHFFFAOYSA-N 0.000 claims 1
- OLANRDBHFUSNDD-UHFFFAOYSA-N 1-[2-[1-(3,5-dimethoxyphenyl)ethylamino]-4-piperazin-1-ylphenyl]-2,2,2-trifluoroethanone Chemical compound COC1=CC(OC)=CC(C(C)NC=2C(=CC=C(C=2)N2CCNCC2)C(=O)C(F)(F)F)=C1 OLANRDBHFUSNDD-UHFFFAOYSA-N 0.000 claims 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- ZMXJKVSBHJILDO-UHFFFAOYSA-N 2,2,2-trifluoro-1-[2-(1-phenylethylamino)-4-piperazin-1-ylphenyl]ethanone Chemical compound C=1C=CC=CC=1C(C)NC(C(=CC=1)C(=O)C(F)(F)F)=CC=1N1CCNCC1 ZMXJKVSBHJILDO-UHFFFAOYSA-N 0.000 claims 1
- HOGFYQBJUWJXNF-UHFFFAOYSA-N 2,2,2-trifluoro-1-[2-[1-(3-methoxyphenyl)ethylamino]-4-piperazin-1-ylphenyl]ethanone Chemical compound COC1=CC=CC(C(C)NC=2C(=CC=C(C=2)N2CCNCC2)C(=O)C(F)(F)F)=C1 HOGFYQBJUWJXNF-UHFFFAOYSA-N 0.000 claims 1
- ZMXJKVSBHJILDO-CQSZACIVSA-N 2,2,2-trifluoro-1-[2-[[(1r)-1-phenylethyl]amino]-4-piperazin-1-ylphenyl]ethanone Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C(=CC=1)C(=O)C(F)(F)F)=CC=1N1CCNCC1 ZMXJKVSBHJILDO-CQSZACIVSA-N 0.000 claims 1
- AHAVPEQFDRIYDE-UHFFFAOYSA-N 2-methyl-n-(2-methylsulfonyl-5-piperazin-1-ylphenyl)-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound CC1CCC2=CC=CC=C2C1NC(C(=CC=1)S(C)(=O)=O)=CC=1N1CCNCC1 AHAVPEQFDRIYDE-UHFFFAOYSA-N 0.000 claims 1
- JFYVDQHWGBSRJG-UHFFFAOYSA-N 2-methylsulfonyl-n-(1-phenylethyl)-5-piperazin-1-ylaniline Chemical compound C=1C=CC=CC=1C(C)NC(C(=CC=1)S(C)(=O)=O)=CC=1N1CCNCC1 JFYVDQHWGBSRJG-UHFFFAOYSA-N 0.000 claims 1
- TZWRXFPFRACRLO-UHFFFAOYSA-N 2-piperazin-1-ylaniline Chemical compound NC1=CC=CC=C1N1CCNCC1 TZWRXFPFRACRLO-UHFFFAOYSA-N 0.000 claims 1
- LCOFMNJNNXWKOC-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-4-amine Chemical compound C1=CC=C2C(N)CCOC2=C1 LCOFMNJNNXWKOC-UHFFFAOYSA-N 0.000 claims 1
- SLOSLDLJAXVPAS-UHFFFAOYSA-N 3-[1-(3,5-dimethoxyphenyl)ethyl]-2-methylsulfonyl-n-phenyl-5-piperazin-1-ylaniline Chemical compound COC1=CC(OC)=CC(C(C)C=2C(=C(NC=3C=CC=CC=3)C=C(C=2)N2CCNCC2)S(C)(=O)=O)=C1 SLOSLDLJAXVPAS-UHFFFAOYSA-N 0.000 claims 1
- IVZONYPLQULMAQ-UHFFFAOYSA-N 3-[1-(3-bromophenyl)propan-2-yl]-2-methylsulfonyl-n-phenyl-5-piperazin-1-ylaniline Chemical compound C=1C(N2CCNCC2)=CC(NC=2C=CC=CC=2)=C(S(C)(=O)=O)C=1C(C)CC1=CC=CC(Br)=C1 IVZONYPLQULMAQ-UHFFFAOYSA-N 0.000 claims 1
- XESHDYUKECENKX-UHFFFAOYSA-N 3-[1-(3-chloro-5-fluoro-2-methoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline Chemical compound COC1=C(Cl)C=C(F)C=C1C(C)C1=CC(N2CCNCC2)=CC(N)=C1S(C)(=O)=O XESHDYUKECENKX-UHFFFAOYSA-N 0.000 claims 1
- PKKJTAYZGYXFQF-UHFFFAOYSA-N 3-[1-(3-chloro-5-methoxyphenyl)ethyl]-2-methylsulfonyl-n-phenyl-5-piperazin-1-ylaniline Chemical compound COC1=CC(Cl)=CC(C(C)C=2C(=C(NC=3C=CC=CC=3)C=C(C=2)N2CCNCC2)S(C)(=O)=O)=C1 PKKJTAYZGYXFQF-UHFFFAOYSA-N 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- SUWYEHHUKFKVAI-UHFFFAOYSA-N 5,8-dimethoxy-n-(2-methylsulfonyl-5-piperazin-1-ylphenyl)-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1CCC=2C(OC)=CC=C(OC)C=2C1NC(C(=CC=1)S(C)(=O)=O)=CC=1N1CCNCC1 SUWYEHHUKFKVAI-UHFFFAOYSA-N 0.000 claims 1
- YYOUCRVVRHCTCQ-UHFFFAOYSA-N 5-(1,4-diazepan-1-yl)-2-nitro-n-(1-phenylethyl)aniline Chemical compound C=1C=CC=CC=1C(C)NC(C(=CC=1)[N+]([O-])=O)=CC=1N1CCCNCC1 YYOUCRVVRHCTCQ-UHFFFAOYSA-N 0.000 claims 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 1
- SBNLNTYLTWPUMX-UHFFFAOYSA-N 6,7-dimethoxy-n-(2-methylsulfonyl-5-piperazin-1-ylphenyl)-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=2C=C(OC)C(OC)=CC=2CCCC1NC(C(=CC=1)S(C)(=O)=O)=CC=1N1CCNCC1 SBNLNTYLTWPUMX-UHFFFAOYSA-N 0.000 claims 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 229960004372 aripiprazole Drugs 0.000 claims 1
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 1
- 229940127236 atypical antipsychotics Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- PMGUPQUHUFCHIA-UHFFFAOYSA-N n-(2-methylsulfonyl-5-piperazin-1-ylphenyl)-1-benzothiophen-3-amine Chemical compound C1=C(NC=2C3=CC=CC=C3SC=2)C(S(=O)(=O)C)=CC=C1N1CCNCC1 PMGUPQUHUFCHIA-UHFFFAOYSA-N 0.000 claims 1
- PZXVWPVXYUQHED-UHFFFAOYSA-N n-(2-methylsulfonyl-5-piperazin-1-ylphenyl)-3,4-dihydro-2h-chromen-4-amine Chemical compound C1=C(NC2C3=CC=CC=C3OCC2)C(S(=O)(=O)C)=CC=C1N1CCNCC1 PZXVWPVXYUQHED-UHFFFAOYSA-N 0.000 claims 1
- YIRYKXYAKSHYTM-UHFFFAOYSA-N n-(2-methylsulfonyl-5-piperazin-1-ylphenyl)naphthalen-1-amine Chemical compound C1=C(NC=2C3=CC=CC=C3C=CC=2)C(S(=O)(=O)C)=CC=C1N1CCNCC1 YIRYKXYAKSHYTM-UHFFFAOYSA-N 0.000 claims 1
- CCNIBVASDCOFKZ-UHFFFAOYSA-N n-(5-fluoro-2-methylsulfonylphenyl)-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound CS(=O)(=O)C1=CC=C(F)C=C1NC1C2=CC=CC=C2CCC1 CCNIBVASDCOFKZ-UHFFFAOYSA-N 0.000 claims 1
- VMSGBDVKRIVPHX-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-2-nitro-5-piperazin-1-ylaniline Chemical compound [O-][N+](=O)C1=CC=C(N2CCNCC2)C=C1NCC1=CC(Cl)=CC(Cl)=C1 VMSGBDVKRIVPHX-UHFFFAOYSA-N 0.000 claims 1
- IYMGCHQFCXKXHN-UHFFFAOYSA-N n-[(3-bromophenyl)methyl]-2-nitro-5-piperazin-1-ylaniline Chemical compound [O-][N+](=O)C1=CC=C(N2CCNCC2)C=C1NCC1=CC=CC(Br)=C1 IYMGCHQFCXKXHN-UHFFFAOYSA-N 0.000 claims 1
- HHTVXYAAUOXPHV-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-2-nitro-5-piperazin-1-ylaniline Chemical compound [O-][N+](=O)C1=CC=C(N2CCNCC2)C=C1NCC1=CC=CC(Cl)=C1 HHTVXYAAUOXPHV-UHFFFAOYSA-N 0.000 claims 1
- NOOQGNRKHZGRHK-UHFFFAOYSA-N n-[1-(3,5-dimethoxyphenyl)ethyl]-2-nitro-5-piperazin-1-ylaniline Chemical compound COC1=CC(OC)=CC(C(C)NC=2C(=CC=C(C=2)N2CCNCC2)[N+]([O-])=O)=C1 NOOQGNRKHZGRHK-UHFFFAOYSA-N 0.000 claims 1
- CILIYXVZDCCXCS-UHFFFAOYSA-N n-[1-(3,5-dimethylphenyl)ethyl]-2-nitro-5-piperazin-1-ylaniline Chemical compound C=1C(C)=CC(C)=CC=1C(C)NC(C(=CC=1)[N+]([O-])=O)=CC=1N1CCNCC1 CILIYXVZDCCXCS-UHFFFAOYSA-N 0.000 claims 1
- IHDHMBPATHUBAY-UHFFFAOYSA-N n-[1-(3-bromophenyl)ethyl]-2-nitro-5-piperazin-1-ylaniline Chemical compound C=1C=CC(Br)=CC=1C(C)NC(C(=CC=1)[N+]([O-])=O)=CC=1N1CCNCC1 IHDHMBPATHUBAY-UHFFFAOYSA-N 0.000 claims 1
- SQIQMPAOZCHUQB-UHFFFAOYSA-N n-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-5-(4-methylpiperazin-1-yl)-2-methylsulfonylaniline Chemical compound COC1=CC(Cl)=CC(C(C)NC=2C(=CC=C(C=2)N2CCN(C)CC2)S(C)(=O)=O)=C1OC SQIQMPAOZCHUQB-UHFFFAOYSA-N 0.000 claims 1
- VHVBLPVPURFSPK-UHFFFAOYSA-N n-[1-(5-chloro-2-methoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline Chemical compound COC1=CC=C(Cl)C=C1C(C)NC1=CC(N2CCNCC2)=CC=C1S(C)(=O)=O VHVBLPVPURFSPK-UHFFFAOYSA-N 0.000 claims 1
- JIWVWJRYFHGHCH-UHFFFAOYSA-N n-[1-(6-chloro-1,3-benzodioxol-4-yl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline;hydrochloride Chemical compound Cl.C=1C(Cl)=CC=2OCOC=2C=1C(C)NC(C(=CC=1)S(C)(=O)=O)=CC=1N1CCNCC1 JIWVWJRYFHGHCH-UHFFFAOYSA-N 0.000 claims 1
- ABIZBBCEFNPBDZ-UHFFFAOYSA-N n-[1-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline Chemical compound C=1C(Cl)=CC=2OCCOC=2C=1C(C)NC(C(=CC=1)S(C)(=O)=O)=CC=1N1CCNCC1 ABIZBBCEFNPBDZ-UHFFFAOYSA-N 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- BSLXKMCHXRCBIH-UHFFFAOYSA-N prx-07034 Chemical compound COC1=CC(Cl)=CC(C(C)NC=2C(=CC=C(C=2)N2CCNCC2)S(C)(=O)=O)=C1OC BSLXKMCHXRCBIH-UHFFFAOYSA-N 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 239000002469 receptor inverse agonist Substances 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000003751 serotonin 6 antagonist Substances 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64695705P | 2005-01-25 | 2005-01-25 | |
| US60/646,957 | 2005-01-25 | ||
| US70185305P | 2005-07-22 | 2005-07-22 | |
| US60/701,853 | 2005-07-22 | ||
| PCT/US2006/002718 WO2006081332A1 (en) | 2005-01-25 | 2006-01-25 | Substituted arylamine compounds and their use as 5-ht6 modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012060984A Division JP2012111784A (ja) | 2005-01-25 | 2012-03-16 | 置換アリールアミン化合物および５−ｈｔ６調節因子としてのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008528517A JP2008528517A (ja) | 2008-07-31 |
| JP2008528517A5 true JP2008528517A5 (enExample) | 2009-03-12 |
| JP5186219B2 JP5186219B2 (ja) | 2013-04-17 |
Family
ID=36406535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007552407A Expired - Fee Related JP5186219B2 (ja) | 2005-01-25 | 2006-01-25 | 置換アリールアミン化合物および５−ｈｔ６調節因子としてのその使用 |
| JP2012060984A Withdrawn JP2012111784A (ja) | 2005-01-25 | 2012-03-16 | 置換アリールアミン化合物および５−ｈｔ６調節因子としてのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012060984A Withdrawn JP2012111784A (ja) | 2005-01-25 | 2012-03-16 | 置換アリールアミン化合物および５−ｈｔ６調節因子としてのその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7968538B2 (enExample) |
| EP (1) | EP1856075A1 (enExample) |
| JP (2) | JP5186219B2 (enExample) |
| KR (1) | KR20070097590A (enExample) |
| AU (1) | AU2006209216A1 (enExample) |
| BR (1) | BRPI0606110A2 (enExample) |
| CA (1) | CA2595607C (enExample) |
| IL (1) | IL184705A0 (enExample) |
| MA (1) | MA29429B1 (enExample) |
| MX (1) | MX2007008279A (enExample) |
| NO (1) | NO20074324L (enExample) |
| NZ (1) | NZ556761A (enExample) |
| RU (1) | RU2440996C2 (enExample) |
| WO (1) | WO2006081332A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| US7153858B2 (en) | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| DE102004009039A1 (de) * | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
| US7488736B2 (en) * | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| DE102004030502A1 (de) * | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| US7576211B2 (en) * | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
| EP1676842A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| KR20070097590A (ko) | 2005-01-25 | 2007-10-04 | 에픽스 델라웨어, 인코포레이티드 | 치환된 아릴아민 화합물 및 5―ｈｔ6 조절제로서의 이의용도 |
| AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| EP2684871B1 (en) | 2006-12-19 | 2016-05-04 | F. Hoffmann-La Roche AG | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives |
| WO2008116833A1 (en) | 2007-03-23 | 2008-10-02 | Abbott Gmbh & Co. Kg | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| EP2103596A1 (en) * | 2008-03-18 | 2009-09-23 | Laboratorios Del. Dr. Esteve, S.A. | Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists |
| ES2353297B1 (es) * | 2008-03-18 | 2011-09-26 | Laboratorios Del Dr. Esteve, S. A. | Procedimiento para la preparación de n-(1-feniletil)anilinas, sales, y solvatos de las mismas útiles como antagonistas de 5-ht6 de serotonina. |
| WO2010065743A2 (en) * | 2008-12-03 | 2010-06-10 | Nanotherapeutics, Inc. | Bicyclic compounds and methods of making and using same |
| BR112012020271A2 (pt) * | 2010-02-11 | 2017-08-29 | Univ Vanderbilt | Benzisoxazóis e azabenzisoxazóis como potencializadores alostéricos de mglur4 composições e métodos de tratamentos de disfunção neurológica |
| TWI458145B (zh) | 2011-12-20 | 2014-10-21 | Ind Tech Res Inst | 超導材料的接合方法 |
| EP3076967B1 (en) | 2013-12-03 | 2021-07-28 | Intra-Cellular Therapies, Inc. | Methods for treating residual symptoms of schizophrenia |
| WO2018071233A1 (en) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018106667A1 (en) | 2016-12-05 | 2018-06-14 | Microbiotix, Inc. | Broad-spectrum inhibitors of filoviruses |
| MX387784B (es) | 2017-03-24 | 2025-03-18 | Intra Celular Therapies Inc | Composiciones novedosas y metodos. |
| IL283725B2 (en) | 2017-06-20 | 2024-04-01 | Imbria Pharmaceuticals Inc | Compositions and methods for increasing efficiency of cardiac metabolism |
| KR101992621B1 (ko) * | 2017-12-07 | 2019-09-27 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
| WO2020047241A1 (en) | 2018-08-29 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
| CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2020081361A1 (en) | 2018-10-17 | 2020-04-23 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| CN114072150A (zh) | 2019-07-07 | 2022-02-18 | 细胞内治疗公司 | 新方法 |
| CN112574201B (zh) * | 2019-09-29 | 2024-04-19 | 四川科伦博泰生物医药股份有限公司 | 芳基胺类化合物、包含其的药物组合物及其制备方法和用途 |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| KR20230134469A (ko) | 2020-11-20 | 2023-09-21 | 2692372 온타리오 인크. | Kras 변형을 위한 방법 및 조성물 |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1211359B (de) * | 1955-11-29 | 1966-02-24 | Oreal | Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar |
| JPH0413669A (ja) | 1990-04-27 | 1992-01-17 | Mitsui Toatsu Chem Inc | 新規ピリミジンジオン誘導体及び該化合物を含有する抗不整脈剤 |
| DE4238994A1 (de) | 1992-11-19 | 1994-05-26 | Basf Ag | Aniline als Markierungsmittel für Mineralöle |
| JPH07300474A (ja) * | 1994-05-02 | 1995-11-14 | Asahi Chem Ind Co Ltd | テトラハイドロキノキサリン誘導体およびその用途 |
| FR2722788B1 (fr) * | 1994-07-20 | 1996-10-04 | Pf Medicament | Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant |
| JPH10507205A (ja) | 1995-08-02 | 1998-07-14 | ホータ．ウリアッヒ イ シイア．エセ．アー． | 抗真菌活性を有する新規カルボンアミド |
| FR2740134B1 (fr) * | 1995-10-18 | 1998-01-09 | Pf Medicament | Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant |
| US6391871B1 (en) | 1996-09-20 | 2002-05-21 | John W. Olney | Preventing neuronal degeneration in Alzheimer's disease |
| US20010051719A1 (en) | 1996-12-19 | 2001-12-13 | Smithkline Beecham P.L.C. | Novel compounds |
| PT971713E (pt) | 1997-03-03 | 2003-09-30 | Eisai Co Ltd | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao |
| FR2761064B1 (fr) * | 1997-03-20 | 1999-06-04 | Pf Medicament | Piperazines derivees d'amines cycliques, leur preparation et leur application comme medicaments |
| BR9813279B1 (pt) * | 1997-10-27 | 2010-11-16 | derivado de homopiperazina, composição farmacêutica, e, uso do derivado de homopiperazina. | |
| JP4135318B2 (ja) * | 1997-12-15 | 2008-08-20 | アステラス製薬株式会社 | 新規なピリミジン−５−カルボキサミド誘導体 |
| IT1304904B1 (it) | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche |
| JP2002534411A (ja) | 1999-01-07 | 2002-10-15 | ワイス | 鬱病の処置のためのアリールピペラジニル−シクロヘキシルインドール誘導体 |
| US6972287B1 (en) | 1999-06-10 | 2005-12-06 | Pfizer Inc. | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| WO2000078728A1 (en) * | 1999-06-22 | 2000-12-28 | Neurosearch A/S | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| US6610713B2 (en) | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| PE20020063A1 (es) * | 2000-06-20 | 2002-01-30 | Upjohn Co | Bis-arilsulfonas como ligandos del receptor de 5-ht |
| US20040122090A1 (en) | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| CA2442717A1 (en) | 2001-03-15 | 2002-09-26 | Saegis Pharmaceuticals, Inc. | Methods for restoring cognitive function following systemic stress |
| US20030095958A1 (en) * | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
| JP4597480B2 (ja) | 2001-05-11 | 2010-12-15 | プロキシマゲン・リミテッド | 肥満、ｉｉ型糖尿病およびｃｎｓ疾患の処置のための新規アリールスルホンアミド化合物 |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| CA2465978C (en) * | 2001-09-14 | 2015-04-07 | Soon Hyung Woo | Inhibitors of histone deacetylase |
| WO2003080060A1 (en) * | 2002-03-20 | 2003-10-02 | Schering Aktiengesellschaft | Substituted piperazine antithrombotic pai-1 inhibitors |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| CN103169708B (zh) | 2002-07-29 | 2018-02-02 | 里格尔药品股份有限公司 | 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
| JP2006516656A (ja) * | 2003-01-28 | 2006-07-06 | アヴェンティス ファーマ エス．エー． | Ｎ−アリールヘテロ芳香族物質、それを含む組成物およびその用途 |
| US7153858B2 (en) | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
| AR043467A1 (es) | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
| GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| JP4677518B2 (ja) | 2003-03-31 | 2011-04-27 | エピックス デラウェア， インコーポレイテッド | 新規ピペリジニルアミノ−チエノ［２，３−ｄ］ピリミジン化合物 |
| EP1635813A4 (en) | 2003-06-06 | 2009-07-01 | Merck & Co Inc | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA |
| WO2005016025A2 (en) | 2003-07-24 | 2005-02-24 | Cargill, Incorporated | A food composition contain lecithin |
| ES2222827B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| US20050209218A1 (en) | 2004-02-13 | 2005-09-22 | Meyerson Laurence R | Methods and compositions for the treatment of psychiatric conditions |
| US7488736B2 (en) | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| US7407966B2 (en) | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7576211B2 (en) | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
| US7598265B2 (en) | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| WO2006042249A2 (en) | 2004-10-08 | 2006-04-20 | Neuromolecular Pharmaceuticals, Inc. | Methods and compositions for treating migraine pain |
| DE602005014382D1 (de) * | 2004-12-21 | 2009-06-18 | Smithkline Beecham Corp | 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren |
| AU2005321966B2 (en) | 2004-12-28 | 2011-11-17 | Atnx Spv, Llc | Compositions and methods of treating cell proliferation disorders |
| EP1695971A1 (en) * | 2004-12-30 | 2006-08-30 | Laboratorios Del Dr. Esteve, S.A. | Substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| EP1676842A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| KR20070097590A (ko) | 2005-01-25 | 2007-10-04 | 에픽스 델라웨어, 인코포레이티드 | 치환된 아릴아민 화합물 및 5―ｈｔ6 조절제로서의 이의용도 |
| JP5731094B2 (ja) | 2005-02-11 | 2015-06-10 | スティーブン・ウィルスＳｔｅｐｈｅｎ ＷＩＬＬＳ | アセチルコリンエステラーゼ阻害剤による微小血管系疾患の治療 |
| US20060194723A1 (en) | 2005-02-28 | 2006-08-31 | Rabinoff Michael D | Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement |
| EP3753561A1 (en) | 2005-04-05 | 2020-12-23 | Yale University | Glutamate modulating agents in the treatment of mental disorders |
| US20060270650A1 (en) | 2005-05-26 | 2006-11-30 | Macneil Tanya | Combination therapy for the treatment of obesity |
| US7919519B2 (en) | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| CA2630714C (en) | 2005-11-23 | 2014-01-14 | Epix Delaware, Inc. | S1p receptor modulating compounds and use thereof |
| CA2646469A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1p receptor modulating compounds |
-
2006
- 2006-01-25 KR KR1020077019390A patent/KR20070097590A/ko not_active Ceased
- 2006-01-25 AU AU2006209216A patent/AU2006209216A1/en not_active Abandoned
- 2006-01-25 WO PCT/US2006/002718 patent/WO2006081332A1/en not_active Ceased
- 2006-01-25 BR BRPI0606110-9A patent/BRPI0606110A2/pt not_active IP Right Cessation
- 2006-01-25 EP EP06719542A patent/EP1856075A1/en not_active Withdrawn
- 2006-01-25 MX MX2007008279A patent/MX2007008279A/es active IP Right Grant
- 2006-01-25 US US11/340,079 patent/US7968538B2/en not_active Expired - Fee Related
- 2006-01-25 CA CA2595607A patent/CA2595607C/en not_active Expired - Fee Related
- 2006-01-25 RU RU2007132161/04A patent/RU2440996C2/ru not_active IP Right Cessation
- 2006-01-25 JP JP2007552407A patent/JP5186219B2/ja not_active Expired - Fee Related
- 2006-01-25 NZ NZ556761A patent/NZ556761A/en not_active IP Right Cessation
-
2007
- 2007-07-18 IL IL184705A patent/IL184705A0/en unknown
- 2007-08-07 MA MA30129A patent/MA29429B1/fr unknown
- 2007-08-24 NO NO20074324A patent/NO20074324L/no not_active Application Discontinuation
-
2011
- 2011-05-10 US US13/104,450 patent/US8604021B2/en not_active Expired - Fee Related
-
2012
- 2012-03-16 JP JP2012060984A patent/JP2012111784A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528517A5 (enExample) | ||
| RU2007132161A (ru) | Замещенные ариламины и их применение в качестве модуляторов 5-ht6-рецептора | |
| RU2439068C2 (ru) | Модуляторы mglur5 | |
| RU2447060C2 (ru) | Ингибиторы сфингозинкиназы | |
| RU2451675C2 (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| RU2008108984A (ru) | Терапевтический агент от диабета | |
| JP2005532982A5 (enExample) | ||
| RU2004127925A (ru) | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек | |
| JP2004517080A5 (enExample) | ||
| RU2006144811A (ru) | Новые цис-имидазолины | |
| JP2010517946A5 (enExample) | ||
| RU2005138134A (ru) | Получение и применение арилалкильных производных кислот для лечения ожирения | |
| RU2010142937A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ | |
| NZ614305A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
| JP2004534755A5 (enExample) | ||
| JP2011518774A5 (enExample) | ||
| JP2005507918A5 (enExample) | ||
| JP2004525951A5 (enExample) | ||
| RU2008137612A (ru) | Амидное производное или его соли | |
| RU2000105266A (ru) | Производные 1-(n-фениламиноалкил)-пиперазина, замещенные в положении 2 фенильного кольца | |
| RU99122343A (ru) | Производные 2-(иминометил)аминофенила, способ их получения, их применение в качестве лекарственных средств и фармацевтические композиции на их основе | |
| JP2005508923A5 (enExample) | ||
| RU2011143740A (ru) | Соединение пиримидина | |
| JP2010519216A (ja) | Ｃｃｒ５拮抗薬のための医薬組成物および方法 | |
| JP2007528387A (ja) | 置換されたヘテロアリール−およびフェニルスルファモイル化合物 |